Roche to buy bowel drugmaker Telavant for $7.1 billion | The Spokesman-Review

Retrieved on: 2023-10-23 18:03:32

Tags for this article:

Roivant Sciences

Research and development in the United States

Pharmaceutical industry

Inflammatory bowel disease

Roche Holding AG

Japan

United States

Click the tags to see associated articles and topics

Roche to buy bowel drugmaker Telavant for $7.1 billion | The Spokesman-Review. View article details on HISWAI: https://www.spokesman.com/stories/2023/oct/23/roche-to-buy-bowel-drugmaker-telavant-for-71-billi/

Excerpt

Roivant owns 75% of Telavant and Pfizer owns the rest. Roivant attracted interest from several large drug companies wanting to purchase a mid-stage ...

Article found on: www.spokesman.com

View Original Article